Clinical Trial Detail

NCT ID NCT03135171
Title Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Michigan Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Pertuzumab + Tocilizumab + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST